Market Overview
The Australia insulin delivery devices market covers products used to administer insulin to patients with diabetes, including traditional syringes, reusable and disposable insulin pens, and insulin pumps. In 2025, the market is valued at approximately USD 722 million, reflecting its role as a mature but gradually expanding segment within the country's broader diabetes care ecosystem. Public health programs subsidize access to many of these devices, making Australia one of the more accessible markets for diabetes technology in the Asia-Pacific region.
- •Market valued at approximately USD 722 million in 2025
- •Projected CAGR of roughly 2.3% through 2031
- •Key product categories include insulin pens, insulin pumps, and conventional syringes
- •Government programs such as the NDSS subsidize device access for patients
Growth Drivers
Australia's diabetes prevalence continues to climb, with over 1.5 million diagnosed cases and millions more at risk, directly increasing demand for insulin delivery devices. The country's aging demographic further amplifies this trend, as type 2 diabetes becomes more prevalent in older populations. Ongoing innovation in smart and connected insulin delivery technologies, combined with government support for digital health solutions, is also shaping market demand.
- •Rising prevalence of both type 1 and type 2 diabetes in the Australian population
- •An aging population contributing to higher diabetes incidence rates
- •Government-subsidized access to devices like continuous glucose monitors and insulin pumps
Segmentation and Regional Analysis
The insulin pens segment is the fastest-growing product category, with a 2024 base revenue of USD 164.6 million and an 8% CAGR projected through 2030. Connected digital diabetes management solutions, including smart insulin pumps and pens integrated with continuous glucose monitoring, represent an emerging sub-market valued at USD 366.4 million in 2025. Overall, the Asia-Pacific region is the fastest-growing geographic segment globally for insulin delivery devices, outpacing other regions at approximately 8.5% CAGR.
- •Insulin pens segment: USD 164.6 million in 2024, 8% CAGR through 2030
- •Digital diabetes management segment: USD 366.4 million in 2025
- •Asia-Pacific is the fastest-growing region globally at approximately 8.5% CAGR
- •Australia-specific diabetes devices market estimated at USD 721.44 million in 2025
Trends and Outlook
What are the recent trends and outlook?
The market is shifting toward smart and automated insulin delivery, with connected pens and pumps increasingly integrated with continuous glucose monitoring and mobile applications. Closed-loop and hybrid closed-loop systems, which automate insulin dosing based on real-time glucose readings, represent the next phase of technological development. The broader Australian diabetes market is projected to reach USD 5.96 billion by 2028 at a 7.14% CAGR, signaling expanding opportunities across the full spectrum of diabetes care, including insulin delivery devices.
- •Growing adoption of smart insulin pens and pumps integrated with continuous glucose monitors
- •Automated and closed-loop insulin delivery systems gaining clinical and commercial momentum
- •Australia's broader diabetes market projected at USD 5.96 billion by 2028
- •Overall market expected to maintain steady growth through the early 2030s
Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.
Connect to an analyst →Market size and forecast are Claight Analysis, informed by public research and industry data. Historical years before 2025 and all forecast years are Claight estimates at the stated CAGR. Retrieved 2026.